Segments - Operations and Assets for Operating Segments and Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2022	Jan. 01, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 185,340	$ 179,744	$ 309,893	$ 329,219	$ 401,332	$ 385,813	$ 442,408	$ 545,165	$ 1,004,196	$ 1,774,718	$ 1,435,413
Operating income (loss)									(226,253)	18,750	57,714
Depreciation and amortization									108,655	78,716	85,362
Loss from investment in investees									(383)	(629)	(480)
Assets	2,167,259				2,399,715				2,167,259	2,399,715
Goodwill	595,851				520,601				595,851	520,601		$ 710,408	$ 718,625
U.S.
Segment Reporting Information [Line Items]
Total revenues									783,207	1,640,354	1,317,766
Ireland
Segment Reporting Information [Line Items]
Total revenues									117,214	32,809	43,920
Chile
Segment Reporting Information [Line Items]
Total revenues									62,044	63,798	44,153
Spain
Segment Reporting Information [Line Items]
Total revenues									22,477	22,682	16,932
Israel
Segment Reporting Information [Line Items]
Total revenues									3,845	3,563	4,251
Mexico
Segment Reporting Information [Line Items]
Total revenues									14,546	11,005	7,865
Other
Segment Reporting Information [Line Items]
Total revenues									863	507	526
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)									(39,640)	(60,266)	(37,689)
Depreciation and amortization									0	0	0
Loss from investment in investees									0	0	0
Assets	154,224				46,672				154,224	46,672
Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)									(12,961)	(19,051)	(43,519)
Depreciation and amortization									68,618	26,427	29,001
Loss from investment in investees									(383)	(629)	(480)
Assets	1,322,531				1,114,460				1,322,531	1,114,460
Goodwill	312,826				237,576				312,826	237,576
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)									(173,652)	98,067	138,922
Depreciation and amortization									40,037	52,289	56,361
Loss from investment in investees									0	0	0
Assets	690,504				1,238,583				690,504	1,238,583
Goodwill	$ 283,025				$ 283,025				283,025	283,025
Services
Segment Reporting Information [Line Items]
Total revenues									755,630	1,607,106	1,262,242
Services | Corporate
Segment Reporting Information [Line Items]
Total revenues									0	0	0
Services | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									0	0	0
Services | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									755,630	1,607,106	1,262,242
Products
Segment Reporting Information [Line Items]
Total revenues									142,845	141,770	119,952
Products | Corporate
Segment Reporting Information [Line Items]
Total revenues									0	0	0
Products | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									142,845	141,770	119,952
Products | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									0	0	0
Transfer Of Intellectual Property And Other [Member]
Segment Reporting Information [Line Items]
Total revenues									105,721	25,842	53,219
Transfer Of Intellectual Property And Other [Member] | Corporate
Segment Reporting Information [Line Items]
Total revenues									0	0	0
Transfer Of Intellectual Property And Other [Member] | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									105,721	25,842	36,979
Transfer Of Intellectual Property And Other [Member] | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues									$ 0	$ 0	$ 16,240